Alkermes Plc (ALKS) Stock: What Does the Chart Say Monday?

Overall market sentiment has been high on Alkermes Plc (ALKS) stock lately. ALKS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Alkermes Plc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ALKS!

See Full ALKS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ALKS Stock Today?

Alkermes Plc (ALKS) stock is trading at $28.92 as of 3:46 PM on Monday, Jan 30, a decline of -$0.10, or -0.36% from the previous closing price of $29.02. Volume today is light. So far 533,081 shares have traded compared to average volume of 1,354,018 shares. The stock has traded between $28.74 and $29.28 so far today.

More About Alkermes Plc

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. Click Here to get the full Stock Report for Alkermes Plc stock.